Patients with CLL that have increased expression of exhaustion markers such as PD-1, T-cell immunoglobulin and mucin domain 3 (TIM-3), and lymphocyte-activation gene 3 (LAG-3)[56] show diminished response to CAR T-cell therapy. This evidence concerns the gene LAG3 and B-cell chronic lymphocytic leukemia.